Laboratorios Farmaceuticos Rovi SA (OTCPK:LABFF)

Q4 2024 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Feb 25, 2025 / 09:00 AM GMT

Release Date Price: $90.61

Transcript

Key Points

Positve

Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) reported a 2% increase in sales of its specialty pharmaceutical business, reaching €427.5 million in 2024.
The company's gross margin improved by 370 basis points in 2024, indicating better cost management and profitability.
Sales of the product Odi doubled in 2024 compared to 2023, showcasing strong market acceptance and growth potential.
Rovi's ESG risk rating improved, placing it 5th among 424 companies in the pharmaceutical industry, highlighting its commitment to sustainability.
The company has entered into a new agreement to support the manufacture of prefilled syringes, expected to positively impact revenues by 20-45% over 2023 sales starting in 2027.

Negative

Total operating revenues fell by 7.9% to €763.7 million in 2024, primarily due to decreased revenues from COVID-19 vaccine manufacturing.
Net profit decreased by 20% to €134.6 million in 2024 compared to 2023, reflecting financial challenges.
The CDMO business experienced a significant decline in sales, attributed to lower revenues from COVID-19 vaccine production and a provision impacting sales figures.
R&D expenses increased by 3% to €25.8 million in 2024, indicating higher costs associated with ongoing clinical trials.
The company expects operating revenue to decrease by a mid-single-digit percentage in 2025, suggesting continued financial pressure.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROVI.MC - Laboratorios Farmaceuticos ROVI SA
Q4 2024 Laboratorios Farmaceuticos ROVI SA Earnings Call
Feb 25, 2025 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning to everybody.

Warm welcome to all those attending the presentation of Robi's 2024 Financial results, which will start in a moment.

I'm Javier Lopez Vermonte, Robbie's deputy Chairman and Chief Financial Officer of the company.

Joining me on today's call are Juan Lopez Vermonte, Rovi's Chairman and CEO, and Marta Camtos, our head of finance.

The presentation will be followed by the Q&A session.

Therefore, if you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform.

Before we begin, Let me remind you that the information presented in this call contains

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.